EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Importance of MTHFD2 Expression in Renal Cell Carcinoma

Onur Ceylan, Remzi Arslan

The New Journal of Urology · 2025

DOI: 10.33719/nju1594236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The New Journal of Urology, 2025. Verfasst von Onur Ceylan und 1 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Renal cell carcinoma (RCC) carries a poor prognosis at advanced stages. Identifying reliable prognostic biomarkers is essential for improved clinical management. Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a key mitochondrial enzyme in the folate cycle, is overexpressed in various rapidly proliferating malignancies. However, its prognostic value in RCC remains underexplored. For this reason, we purposed to search the prognostic role of MTHFD2 expression in RCC. Materials and Methods: This study included 124 RCC patients who applied radical nephrectomy between 2015 and 2020. Immunohistochemical analysis of MTHFD2 expression was performed on paraffin-embedded tumor samples. Expression levels were classified using a histoscore-based system: low (grades 0–1) and high (grades 2–3). Correlations between MTHFD2 expression and clinical/pathological parameters were evaluated, and survival analysis was conducted.

Results

MTHFD2 overexpression was detected in 53% of tumors and was absent in adjacent non-tumor tissues. High expression was significantly associated with adverse prognostic features, including higher histological grade, sarcomatoid differentiation, advanced pT stage, and presence of distant metastases (all p < 0.05). Patients with high MTHFD2 expression had significantly reduced overall survival (p < 0.001). Remarkably, early-stage tumors (pT1–2) with high MTHFD2 expression were linked to shorter survival compared to more advanced tumors (pT3–4) with low expression.

Conclusion

Our results pointed out that high expression of MTHFD2 is associated with poor prognosis in RCC and may function as an independent prognostic biomarker. These findings underscore the potential of MTHFD2 in risk stratification and as a therapeutic target in RCC.

Zitieren

APA

Ceylan, O., & Arslan, R. (2025). The Importance of MTHFD2 Expression in Renal Cell Carcinoma. The New Journal of Urology. https://doi.org/10.33719/nju1594236

Vancouver

Ceylan O, Arslan R. The Importance of MTHFD2 Expression in Renal Cell Carcinoma. The New Journal of Urology. 2025. doi:10.33719/nju1594236

BibTeX
@article{Ceylan2025,
  author = {Ceylan, Onur and Arslan, Remzi},
  title = {The Importance of MTHFD2 Expression in Renal Cell Carcinoma},
  journal = {The New Journal of Urology},
  year = {2025},
  doi = {10.33719/nju1594236}
}
Kostenlos starten →